EUCTR2011-004377-84-NL进行中（未招募）1 期
A RANDOMIZED, OPEN-LABEL, MULTICENTER,PHASE II TRIAL EVALUATING THE SAFETY ANDACTIVITY OF DCDT2980S IN COMBINATIONWITH RITUXIMAB OR DCDS4501A INCOMBINATION WITH RITUXIMAB IN PATIENTSWITH RELAPSED OR REFRACTORY B-CELLNON-HODGKIN’S LYMPHOMA
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 230
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Life expectancy of at least 12 weeks;
- •- Age = 18 years;
- •- History of histologically documented relapsed or refractory Grades 1-3a
- •FL, or relapsed or refractory DLBCL;
- •- Must have at least one bi-dimensionally measurable lesion;
- •- Adequate hepatic, renal and cardiopulmonary function;
- •- For all men and women of childbearing potential use of adequate
- •methods of contraception.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 40
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range 80
排除标准
- •- Prior use of any monoclonal antibody, radioimmunoconjugate or
- •antibody-drug conjugate within 4 weeks before Cycle 1 Day1;
- •- Treatment with radiotherapy, chemotherapy, immunotherapy, or an
- •investigational anti-cancer agent within 2 weeks prior to Cycle 1 Day 1;
- •- Prior autologous stem cell transplant within 100 days prior to Cycle 1
- •- Prior allogeneic stem cell transplant;
- •- Eligibility for autologous stem cell transplant.
研究者
相似试验
进行中（未招募）
1 期
A randomized study of the safety and efficacy of a novel drug, DNIB0600A, compared to chemotherapy when given intravenously to patients with ovarian cancer.Platinum Resistant Ovarian CancerMedDRA version: 16.1Level: SOCClassification code 10029104Term: Neoplasms benign, malignant and unspecified (incl cysts and polyps)System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 16.1Level: PTClassification code 10033128Term: Ovarian cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2012-005776-34-GBGenentech, Inc.92
进行中（未招募）
1 期
A randomized study of the safety and efficacy of a novel drug, DNIB0600A, compared to chemotherapy when given intravenously to patients with ovarian cancer.EUCTR2012-005776-34-BEGenentech, Inc.92
进行中（未招募）
1 期
A randomized study of the safety and efficacy of a novel drug, DNIB0600A, compared to chemotherapy when given intravenously to patients with ovarian cancer.Platinum Resistant Ovarian CancerMedDRA version: 17.0Level: SOCClassification code 10029104Term: Neoplasms benign, malignant and unspecified (incl cysts and polyps)System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 17.0Level: PTClassification code 10033128Term: Ovarian cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2012-005776-34-PLGenentech, Inc.92
进行中（未招募）
1 期
A randomized study of the safety and efficacy of a novel drug, DNIB0600A, compared to chemotherapy when given intravenously to patients with ovarian cancer.Platinum Resistant Ovarian CancerMedDRA version: 16.1Level: SOCClassification code 10029104Term: Neoplasms benign, malignant and unspecified (incl cysts and polyps)System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 16.1Level: PTClassification code 10033128Term: Ovarian cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2012-005776-34-FRGenentech, Inc.92
进行中（未招募）
1 期
A randomized study of the safety and efficacy of a novel drug, DNIB0600A, compared to chemotherapy when given intravenously to patients with ovarian cancer.EUCTR2012-005776-34-ESRoche Farma, S.A en nombre de Genentech, Inc.92